Baird Initiates Coverage On ResMed with Outperform Rating, Announces Price Target of $280
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joe Vruwink has initiated coverage on ResMed (NYSE:RMD) with an Outperform rating and set a price target of $280.

September 24, 2024 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird has initiated coverage on ResMed with an Outperform rating and a price target of $280, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $280 by Baird suggests a positive sentiment towards ResMed's stock. This is likely to influence investor perception positively, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100